Read the most outstanding articles from SOLACI-SBHCI 2023 Congress. In this case, check the presentation by Dr. Eberhard Grube, entitled “Mitral Valve Interventions beyond the TEER Era: Time to Re-Evaluate Innovation Priorities?”
Mitral Valve Edge to Edge Repair for Papillary Muscle Rupture after Acute Myocardial Infarction
With an approximate incidence of 0.05% to 0.25%, post-acute myocardial infarction (AMI) mitral valve failure caused by papillary muscle rupture is not exactly common. However, it is associated to high mortality rate, ranging between 36% and 80%. Current guidelines recommend surgical treatment, but more often than not surgery involves prohibitive or extremely high risk, with<a href="https://solaci.org/en/2023/07/14/mitral-valve-edge-to-edge-repair-for-papillary-muscle-rupture-after-acute-myocardial-infarction/" title="Read more" >...</a>
Transcatheter Mitral Valve Replacement vs. Medical Therapy
Mitral valve regurgitation (MR) is a common cause behind heart failure and is associated to hospitalization for heart failure and higher mortality. Transcatheter edge-to-edge repair (TEER), together with guideline-directed medical therapy (GDMT) has been shown beneficial in high risk patients, according to the COAPT study. However, there is a significant group of patients that make<a href="https://solaci.org/en/2023/07/04/transcatheter-mitral-valve-replacement-vs-medical-therapy/" title="Read more" >...</a>
See Percutaneous Valve Intervention, a Nurse’s Point of View
You can now relive our virtual event on Percutaneous Valvular Intervention, a Nurse’s Point of View on our YouTube channel. The event was carried out by the SOLACI Chapter of Technicians, Nurses and Medical Technologists and had the participation of important speakers from all over LATAM. See the full video below. 🚀 Percutaneous Valve Intervention,<a href="https://solaci.org/en/2023/06/22/see-percutaneous-valve-intervention-a-nurses-point-of-view/" title="Read more" >...</a>
06/16 | SOLACI Webinar – Percutaneous Valve Interventionism: Nurses’ Perspective
SOLACI’s nurses, technicians and medical technicians invite you to take part in a new educational activity focused on percutaneous valve interventionism. The event will take place on June 16 at 7 pm (Argentinian, Brazilian time) featuring experts from Argentina, Uruguay, Chile, Colombia and Venezuela. Certificates of attendance will be issued.
Mitral Valve Surgery after Edge-to-Edge Repair
In last few years, transcatheter edge-to-edge repair (TEER) with MitraClip has been shown safe and effective, both for primary and secondary mitral valve regurgitation (MR), given the increasing interventionist and echocardiographer experience. However, there is a group of patients that require surgery after failed TEER, either because of bad evolution or because device implantation<a href="https://solaci.org/en/2023/05/30/mitral-valve-surgery-after-edge-to-edge-repair/" title="Read more" >...</a>
EuroPCR 2023 | TAVR in TAVR Results with Balloon-Expandable Valves
With the expansion of transcatheter aortic valve replacement (TAVR) use in the low-risk population, more patients will need repeat valve replacement in the future, making it paramount to understand the performance of repeat TAVR. Currently, this information is limited. The aim of this study was to analyze the real-world experience of performing a second TAVR<a href="https://solaci.org/en/2023/05/24/europcr-2023-tavr-in-tavr-results-with-balloon-expandable-valves/" title="Read more" >...</a>
Echo- Stress during Edge-to-Edge Mitral Valve Repair Can Be Useful
Transcatheter edge-to-edge mitral valve repair with Mitraclip has become a valid strategy to treat mitral valve regurgitation (MR) when surgery is not viable. However, after discharge, residual MR (>moderate) can affect over 10% of patients, because of the use of anesthesia, which alters pre and post procedural measurements. In this context, eco-stress could become a<a href="https://solaci.org/en/2023/05/23/echo-stress-during-edge-to-edge-mitral-valve-repair-can-be-useful/" title="Read more" >...</a>
EuroPCR 2023 | TAVR in Patients with Bicuspid Aortic Valve Stenosis
Bicuspid aortic valve (BAV) stenosis is the most common congenital valve disease, affecting up to 2% of the population. Patients with BAV disease undergoing transcatheter aortic valve replacement (TAVR) account for 0.5%. In this context, TAVR data on BAV stenosis patients has been limited to observational studies on first generation valves that had resulted in<a href="https://solaci.org/en/2023/05/21/europcr-2023-tavr-in-patients-with-bicuspid-aortic-valve-stenosis/" title="Read more" >...</a>
EuroPCR 2023 | Events after Redo TAVR in Balloon-Expandable Valves
With the treatment of aortic valve disease in younger patients, a significant number of them will need redo TAVR at some point in their life. However, to date there are few data on redo TAVR. The aims of this study was to look at real life experience on redo TAVR with balloon-expandable SAPIEN valves and<a href="https://solaci.org/en/2023/05/17/europcr-2023-events-after-redo-tavr-in-balloon-expandable-valves/" title="Read more" >...</a>